APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiasthmatic Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antiasthmatic Drug Market Analysis and Forecast 2026-2032

2 January 2026201 pages

Choose your research edition.

Industry ResearchAntiasthmatic Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiasthmatic Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antiasthmatic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiasthmatic Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiasthmatic Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Antiasthmatic Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antiasthmatic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antiasthmatic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antiasthmatic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antiasthmatic Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antiasthmatic Drug include Ruiyang Pharmaceutical Co., Ltd, Novartis AG, Roche, Lunan Pharmaceutical Group Co., Ltd, Kaifeng Kangnuo Pharmaceutical Co., Ltd, GlaxoSmithKline, Fuhe Group, Chengdu Huayu Pharmaceutical Co., Ltd and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antiasthmatic Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antiasthmatic Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Antiasthmatic Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiasthmatic Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antiasthmatic Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antiasthmatic Drug revenue, projected growth trends, production technology, application and end-user industry.

Antiasthmatic Drug Segment by Company

Ruiyang Pharmaceutical Co., Ltd

Novartis AG

Roche

Lunan Pharmaceutical Group Co., Ltd

Kaifeng Kangnuo Pharmaceutical Co., Ltd

GlaxoSmithKline

Fuhe Group

Chengdu Huayu Pharmaceutical Co., Ltd

AstraZeneca

Teva Pharmaceutical Industries Ltd

Mundipharma Pharmaceuticals Ltd.

MSD

Kyorin Pharmaceutical Co.,Ltd.

Kissei Pharmaceutical Co.Ltd.

Daiichi Sankyo Company Limited

Covis Pharmaceutical Inc

Chiesi GmbH

Boehringer Ingelheim Pharma GmbH&Co.KG

Akorn Pharmaceutical Co.Ltd.

ABC Farmaceutici Spa

Antiasthmatic Drug Segment by Type

Anti-allergic Antiasthmatic

Anti-inflammatory Antiasthmatic

Bronchodilators

Antiasthmatic Drug Segment by Application

Hospital

Clinic

Other

Antiasthmatic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiasthmatic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiasthmatic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiasthmatic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antiasthmatic Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antiasthmatic Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiasthmatic Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antiasthmatic Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Anti-allergic Antiasthmatic Major Player Table 3. Anti-inflammatory Antiasthmatic Major Player Table 4. Bronchodilators Major Player Table 5. Global Antiasthmatic Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Other Major Player Table 9. Antiasthmatic Drug Industry Trends Table 10. Antiasthmatic Drug Industry Drivers Table 11. Antiasthmatic Drug Industry Opportunities and Challenges Table 12. Antiasthmatic Drug Industry Restraints Table 13. Global Antiasthmatic Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antiasthmatic Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antiasthmatic Drug Market Share by Region (2021-2026) Table 16. Global Antiasthmatic Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antiasthmatic Drug Market Share by Region (2027-2032) Table 18. Global Antiasthmatic Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Antiasthmatic Drug Revenue Market Share by Players (2021-2026) Table 20. Global Antiasthmatic Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Antiasthmatic Drug Key Players Headquarters & Area Served Table 22. Global Antiasthmatic Drug Players, Product Type & Application Table 23. Global Antiasthmatic Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Antiasthmatic Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Antiasthmatic Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antiasthmatic Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Antiasthmatic Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Antiasthmatic Drug Revenue Market Share by Type (2021-2026) Table 30. Global Antiasthmatic Drug Revenue Market Share by Type (2027-2032) Table 31. Global Antiasthmatic Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antiasthmatic Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Antiasthmatic Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Antiasthmatic Drug Revenue Market Share by Application (2021-2026) Table 35. Global Antiasthmatic Drug Revenue Market Share by Application (2027-2032) Table 36. Ruiyang Pharmaceutical Co., Ltd Company Information Table 37. Ruiyang Pharmaceutical Co., Ltd Business Overview Table 38. Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio Table 40. Ruiyang Pharmaceutical Co., Ltd Recent Development Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis AG Antiasthmatic Drug Product Portfolio Table 45. Novartis AG Recent Development Table 46. Roche Company Information Table 47. Roche Business Overview Table 48. Roche Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Roche Antiasthmatic Drug Product Portfolio Table 50. Roche Recent Development Table 51. Lunan Pharmaceutical Group Co., Ltd Company Information Table 52. Lunan Pharmaceutical Group Co., Ltd Business Overview Table 53. Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Product Portfolio Table 55. Lunan Pharmaceutical Group Co., Ltd Recent Development Table 56. Kaifeng Kangnuo Pharmaceutical Co., Ltd Company Information Table 57. Kaifeng Kangnuo Pharmaceutical Co., Ltd Business Overview Table 58. Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio Table 60. Kaifeng Kangnuo Pharmaceutical Co., Ltd Recent Development Table 61. GlaxoSmithKline Company Information Table 62. GlaxoSmithKline Business Overview Table 63. GlaxoSmithKline Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. GlaxoSmithKline Antiasthmatic Drug Product Portfolio Table 65. GlaxoSmithKline Recent Development Table 66. Fuhe Group Company Information Table 67. Fuhe Group Business Overview Table 68. Fuhe Group Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Fuhe Group Antiasthmatic Drug Product Portfolio Table 70. Fuhe Group Recent Development Table 71. Chengdu Huayu Pharmaceutical Co., Ltd Company Information Table 72. Chengdu Huayu Pharmaceutical Co., Ltd Business Overview Table 73. Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio Table 75. Chengdu Huayu Pharmaceutical Co., Ltd Recent Development Table 76. AstraZeneca Company Information Table 77. AstraZeneca Business Overview Table 78. AstraZeneca Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. AstraZeneca Antiasthmatic Drug Product Portfolio Table 80. AstraZeneca Recent Development Table 81. Teva Pharmaceutical Industries Ltd Company Information Table 82. Teva Pharmaceutical Industries Ltd Business Overview Table 83. Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Product Portfolio Table 85. Teva Pharmaceutical Industries Ltd Recent Development Table 86. Mundipharma Pharmaceuticals Ltd. Company Information Table 87. Mundipharma Pharmaceuticals Ltd. Business Overview Table 88. Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Product Portfolio Table 90. Mundipharma Pharmaceuticals Ltd. Recent Development Table 91. MSD Company Information Table 92. MSD Business Overview Table 93. MSD Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. MSD Antiasthmatic Drug Product Portfolio Table 95. MSD Recent Development Table 96. Kyorin Pharmaceutical Co.,Ltd. Company Information Table 97. Kyorin Pharmaceutical Co.,Ltd. Business Overview Table 98. Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Product Portfolio Table 100. Kyorin Pharmaceutical Co.,Ltd. Recent Development Table 101. Kissei Pharmaceutical Co.Ltd. Company Information Table 102. Kissei Pharmaceutical Co.Ltd. Business Overview Table 103. Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio Table 105. Kissei Pharmaceutical Co.Ltd. Recent Development Table 106. Daiichi Sankyo Company Limited Company Information Table 107. Daiichi Sankyo Company Limited Business Overview Table 108. Daiichi Sankyo Company Limited Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Daiichi Sankyo Company Limited Antiasthmatic Drug Product Portfolio Table 110. Daiichi Sankyo Company Limited Recent Development Table 111. Covis Pharmaceutical Inc Company Information Table 112. Covis Pharmaceutical Inc Business Overview Table 113. Covis Pharmaceutical Inc Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Covis Pharmaceutical Inc Antiasthmatic Drug Product Portfolio Table 115. Covis Pharmaceutical Inc Recent Development Table 116. Chiesi GmbH Company Information Table 117. Chiesi GmbH Business Overview Table 118. Chiesi GmbH Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Chiesi GmbH Antiasthmatic Drug Product Portfolio Table 120. Chiesi GmbH Recent Development Table 121. Boehringer Ingelheim Pharma GmbH&Co.KG Company Information Table 122. Boehringer Ingelheim Pharma GmbH&Co.KG Business Overview Table 123. Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Product Portfolio Table 125. Boehringer Ingelheim Pharma GmbH&Co.KG Recent Development Table 126. Akorn Pharmaceutical Co.Ltd. Company Information Table 127. Akorn Pharmaceutical Co.Ltd. Business Overview Table 128. Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio Table 130. Akorn Pharmaceutical Co.Ltd. Recent Development Table 131. ABC Farmaceutici Spa Company Information Table 132. ABC Farmaceutici Spa Business Overview Table 133. ABC Farmaceutici Spa Antiasthmatic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. ABC Farmaceutici Spa Antiasthmatic Drug Product Portfolio Table 135. ABC Farmaceutici Spa Recent Development Table 136. North America Antiasthmatic Drug Revenue by Type (2021-2026) & (US$ Million) Table 137. North America Antiasthmatic Drug Revenue by Type (2027-2032) & (US$ Million) Table 138. North America Antiasthmatic Drug Revenue by Application (2021-2026) & (US$ Million) Table 139. North America Antiasthmatic Drug Revenue by Application (2027-2032) & (US$ Million) Table 140. North America Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. North America Antiasthmatic Drug Revenue by Country (2021-2026) & (US$ Million) Table 142. North America Antiasthmatic Drug Revenue by Country (US$ Million) & (2027-2032) Table 143. Europe Antiasthmatic Drug Revenue by Type (2021-2026) & (US$ Million) Table 144. Europe Antiasthmatic Drug Revenue by Type (2027-2032) & (US$ Million) Table 145. Europe Antiasthmatic Drug Revenue by Application (2021-2026) & (US$ Million) Table 146. Europe Antiasthmatic Drug Revenue by Application (2027-2032) & (US$ Million) Table 147. Europe Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Antiasthmatic Drug Revenue by Country (2021-2026) & (US$ Million) Table 149. Europe Antiasthmatic Drug Revenue by Country (US$ Million) & (2027-2032) Table 150. China Antiasthmatic Drug Revenue by Type (2021-2026) & (US$ Million) Table 151. China Antiasthmatic Drug Revenue by Type (2027-2032) & (US$ Million) Table 152. China Antiasthmatic Drug Revenue by Application (2021-2026) & (US$ Million) Table 153. China Antiasthmatic Drug Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Antiasthmatic Drug Revenue by Type (2021-2026) & (US$ Million) Table 155. Asia Antiasthmatic Drug Revenue by Type (2027-2032) & (US$ Million) Table 156. Asia Antiasthmatic Drug Revenue by Application (2021-2026) & (US$ Million) Table 157. Asia Antiasthmatic Drug Revenue by Application (2027-2032) & (US$ Million) Table 158. Asia Antiasthmatic Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Antiasthmatic Drug Revenue by Region (US$ Million) & (2021-2026) Table 160. Asia Antiasthmatic Drug Revenue by Region (US$ Million) & (2027-2032) Table 161. SAMEA Antiasthmatic Drug Revenue by Type (2021-2026) & (US$ Million) Table 162. SAMEA Antiasthmatic Drug Revenue by Type (2027-2032) & (US$ Million) Table 163. SAMEA Antiasthmatic Drug Revenue by Application (2021-2026) & (US$ Million) Table 164. SAMEA Antiasthmatic Drug Revenue by Application (2027-2032) & (US$ Million) Table 165. SAMEA Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. SAMEA Antiasthmatic Drug Revenue by Country (2021-2026) & (US$ Million) Table 167. SAMEA Antiasthmatic Drug Revenue by Country (US$ Million) & (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Antiasthmatic Drug Image Figure 2. Global Antiasthmatic Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiasthmatic Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Anti-allergic Antiasthmatic Image Figure 5. Anti-inflammatory Antiasthmatic Image Figure 6. Bronchodilators Image Figure 7. Global Antiasthmatic Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antiasthmatic Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Other Image Figure 12. Global Antiasthmatic Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Antiasthmatic Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antiasthmatic Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Antiasthmatic Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Antiasthmatic Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Antiasthmatic Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Antiasthmatic Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Antiasthmatic Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antiasthmatic Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Antiasthmatic Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Antiasthmatic Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Antiasthmatic Drug Revenue Share by Type (2021-2032) Figure 25. North America Antiasthmatic Drug Revenue Share by Application (2021-2032) Figure 26. North America Antiasthmatic Drug Revenue Share by Country (2021-2032) Figure 27. United States Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Antiasthmatic Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Antiasthmatic Drug Revenue Share by Type (2021-2032) Figure 32. Europe Antiasthmatic Drug Revenue Share by Application (2021-2032) Figure 33. Europe Antiasthmatic Drug Revenue Share by Country (2021-2032) Figure 34. Germany Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Antiasthmatic Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Antiasthmatic Drug Revenue Share by Type (2021-2032) Figure 44. China Antiasthmatic Drug Revenue Share by Application (2021-2032) Figure 45. Asia Antiasthmatic Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Antiasthmatic Drug Revenue Share by Type (2021-2032) Figure 47. Asia Antiasthmatic Drug Revenue Share by Application (2021-2032) Figure 48. Asia Antiasthmatic Drug Revenue Share by Region (2021-2032) Figure 49. Japan Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Antiasthmatic Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Antiasthmatic Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Antiasthmatic Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Antiasthmatic Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Antiasthmatic Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-allergic Antiasthmatic
  • Anti-inflammatory Antiasthmatic
  • Bronchodilators
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Ruiyang Pharmaceutical Co., Ltd
  • Novartis AG
  • Roche
  • Lunan Pharmaceutical Group Co., Ltd
  • Kaifeng Kangnuo Pharmaceutical Co., Ltd
  • GlaxoSmithKline
  • Fuhe Group
  • Chengdu Huayu Pharmaceutical Co., Ltd
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd
  • Mundipharma Pharmaceuticals Ltd.
  • MSD
  • Kyorin Pharmaceutical Co.,Ltd.
  • Kissei Pharmaceutical Co.Ltd.
  • Daiichi Sankyo Company Limited
  • Covis Pharmaceutical Inc
  • Chiesi GmbH
  • Boehringer Ingelheim Pharma GmbH&Co.KG
  • Akorn Pharmaceutical Co.Ltd.
  • ABC Farmaceutici Spa

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antiasthmatic Drug Market by Type
  3. 1.2.1 Global Antiasthmatic Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Anti-allergic Antiasthmatic
  5. 1.2.3 Anti-inflammatory Antiasthmatic
  6. 1.2.4 Bronchodilators
  7. 1.3 Antiasthmatic Drug Market by Application
  8. 1.3.1 Global Antiasthmatic Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Antiasthmatic Drug Market Dynamics
  1. 2.1 Antiasthmatic Drug Industry Trends
  2. 2.2 Antiasthmatic Drug Industry Drivers
  3. 2.3 Antiasthmatic Drug Industry Opportunities and Challenges
  4. 2.4 Antiasthmatic Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antiasthmatic Drug Market Perspective (2021-2032)
  2. 3.2 Global Antiasthmatic Drug Growth Trends by Region
  3. 3.2.1 Global Antiasthmatic Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antiasthmatic Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Antiasthmatic Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antiasthmatic Drug Revenue by Players
  2. 4.1.1 Global Antiasthmatic Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Antiasthmatic Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antiasthmatic Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antiasthmatic Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antiasthmatic Drug Key Players Headquarters & Area Served
  7. 4.4 Global Antiasthmatic Drug Players, Product Type & Application
  8. 4.5 Global Antiasthmatic Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antiasthmatic Drug Market CR5 and HHI
  11. 4.6.3 2025 Antiasthmatic Drug Tier 1, Tier 2, and Tier 3
5 Antiasthmatic Drug Market Size by Type
  1. 5.1 Global Antiasthmatic Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antiasthmatic Drug Revenue by Type (2021-2032)
  3. 5.3 Global Antiasthmatic Drug Revenue Market Share by Type (2021-2032)
6 Antiasthmatic Drug Market Size by Application
  1. 6.1 Global Antiasthmatic Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antiasthmatic Drug Revenue by Application (2021-2032)
  3. 6.3 Global Antiasthmatic Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Ruiyang Pharmaceutical Co., Ltd
  2. 7.1.1 Ruiyang Pharmaceutical Co., Ltd Company Information
  3. 7.1.2 Ruiyang Pharmaceutical Co., Ltd Business Overview
  4. 7.1.3 Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
  6. 7.1.5 Ruiyang Pharmaceutical Co., Ltd Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Antiasthmatic Drug Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Roche
  14. 7.3.1 Roche Company Information
  15. 7.3.2 Roche Business Overview
  16. 7.3.3 Roche Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Roche Antiasthmatic Drug Product Portfolio
  18. 7.3.5 Roche Recent Developments
  19. 7.4 Lunan Pharmaceutical Group Co., Ltd
  20. 7.4.1 Lunan Pharmaceutical Group Co., Ltd Company Information
  21. 7.4.2 Lunan Pharmaceutical Group Co., Ltd Business Overview
  22. 7.4.3 Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Product Portfolio
  24. 7.4.5 Lunan Pharmaceutical Group Co., Ltd Recent Developments
  25. 7.5 Kaifeng Kangnuo Pharmaceutical Co., Ltd
  26. 7.5.1 Kaifeng Kangnuo Pharmaceutical Co., Ltd Company Information
  27. 7.5.2 Kaifeng Kangnuo Pharmaceutical Co., Ltd Business Overview
  28. 7.5.3 Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
  30. 7.5.5 Kaifeng Kangnuo Pharmaceutical Co., Ltd Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Antiasthmatic Drug Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Fuhe Group
  38. 7.7.1 Fuhe Group Company Information
  39. 7.7.2 Fuhe Group Business Overview
  40. 7.7.3 Fuhe Group Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Fuhe Group Antiasthmatic Drug Product Portfolio
  42. 7.7.5 Fuhe Group Recent Developments
  43. 7.8 Chengdu Huayu Pharmaceutical Co., Ltd
  44. 7.8.1 Chengdu Huayu Pharmaceutical Co., Ltd Company Information
  45. 7.8.2 Chengdu Huayu Pharmaceutical Co., Ltd Business Overview
  46. 7.8.3 Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
  48. 7.8.5 Chengdu Huayu Pharmaceutical Co., Ltd Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Antiasthmatic Drug Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 Teva Pharmaceutical Industries Ltd
  56. 7.10.1 Teva Pharmaceutical Industries Ltd Company Information
  57. 7.10.2 Teva Pharmaceutical Industries Ltd Business Overview
  58. 7.10.3 Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Product Portfolio
  60. 7.10.5 Teva Pharmaceutical Industries Ltd Recent Developments
  61. 7.11 Mundipharma Pharmaceuticals Ltd.
  62. 7.11.1 Mundipharma Pharmaceuticals Ltd. Company Information
  63. 7.11.2 Mundipharma Pharmaceuticals Ltd. Business Overview
  64. 7.11.3 Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Product Portfolio
  66. 7.11.5 Mundipharma Pharmaceuticals Ltd. Recent Developments
  67. 7.12 MSD
  68. 7.12.1 MSD Company Information
  69. 7.12.2 MSD Business Overview
  70. 7.12.3 MSD Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 MSD Antiasthmatic Drug Product Portfolio
  72. 7.12.5 MSD Recent Developments
  73. 7.13 Kyorin Pharmaceutical Co.,Ltd.
  74. 7.13.1 Kyorin Pharmaceutical Co.,Ltd. Company Information
  75. 7.13.2 Kyorin Pharmaceutical Co.,Ltd. Business Overview
  76. 7.13.3 Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Product Portfolio
  78. 7.13.5 Kyorin Pharmaceutical Co.,Ltd. Recent Developments
  79. 7.14 Kissei Pharmaceutical Co.Ltd.
  80. 7.14.1 Kissei Pharmaceutical Co.Ltd. Company Information
  81. 7.14.2 Kissei Pharmaceutical Co.Ltd. Business Overview
  82. 7.14.3 Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio
  84. 7.14.5 Kissei Pharmaceutical Co.Ltd. Recent Developments
  85. 7.15 Daiichi Sankyo Company Limited
  86. 7.15.1 Daiichi Sankyo Company Limited Company Information
  87. 7.15.2 Daiichi Sankyo Company Limited Business Overview
  88. 7.15.3 Daiichi Sankyo Company Limited Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Daiichi Sankyo Company Limited Antiasthmatic Drug Product Portfolio
  90. 7.15.5 Daiichi Sankyo Company Limited Recent Developments
  91. 7.16 Covis Pharmaceutical Inc
  92. 7.16.1 Covis Pharmaceutical Inc Company Information
  93. 7.16.2 Covis Pharmaceutical Inc Business Overview
  94. 7.16.3 Covis Pharmaceutical Inc Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Covis Pharmaceutical Inc Antiasthmatic Drug Product Portfolio
  96. 7.16.5 Covis Pharmaceutical Inc Recent Developments
  97. 7.17 Chiesi GmbH
  98. 7.17.1 Chiesi GmbH Company Information
  99. 7.17.2 Chiesi GmbH Business Overview
  100. 7.17.3 Chiesi GmbH Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Chiesi GmbH Antiasthmatic Drug Product Portfolio
  102. 7.17.5 Chiesi GmbH Recent Developments
  103. 7.18 Boehringer Ingelheim Pharma GmbH&Co.KG
  104. 7.18.1 Boehringer Ingelheim Pharma GmbH&Co.KG Company Information
  105. 7.18.2 Boehringer Ingelheim Pharma GmbH&Co.KG Business Overview
  106. 7.18.3 Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Product Portfolio
  108. 7.18.5 Boehringer Ingelheim Pharma GmbH&Co.KG Recent Developments
  109. 7.19 Akorn Pharmaceutical Co.Ltd.
  110. 7.19.1 Akorn Pharmaceutical Co.Ltd. Company Information
  111. 7.19.2 Akorn Pharmaceutical Co.Ltd. Business Overview
  112. 7.19.3 Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio
  114. 7.19.5 Akorn Pharmaceutical Co.Ltd. Recent Developments
  115. 7.20 ABC Farmaceutici Spa
  116. 7.20.1 ABC Farmaceutici Spa Company Information
  117. 7.20.2 ABC Farmaceutici Spa Business Overview
  118. 7.20.3 ABC Farmaceutici Spa Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 ABC Farmaceutici Spa Antiasthmatic Drug Product Portfolio
  120. 7.20.5 ABC Farmaceutici Spa Recent Developments
8 North America
  1. 8.1 North America Antiasthmatic Drug Revenue (2021-2032)
  2. 8.2 North America Antiasthmatic Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Antiasthmatic Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Antiasthmatic Drug Revenue by Type (2027-2032)
  5. 8.3 North America Antiasthmatic Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Antiasthmatic Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Antiasthmatic Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Antiasthmatic Drug Revenue by Application (2027-2032)
  9. 8.5 North America Antiasthmatic Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Antiasthmatic Drug Revenue by Country
  11. 8.6.1 North America Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antiasthmatic Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Antiasthmatic Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Antiasthmatic Drug Revenue (2021-2032)
  2. 9.2 Europe Antiasthmatic Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antiasthmatic Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antiasthmatic Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Antiasthmatic Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antiasthmatic Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antiasthmatic Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antiasthmatic Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Antiasthmatic Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antiasthmatic Drug Revenue by Country
  11. 9.6.1 Europe Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antiasthmatic Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antiasthmatic Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Antiasthmatic Drug Revenue (2021-2032)
  2. 10.2 China Antiasthmatic Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Antiasthmatic Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Antiasthmatic Drug Revenue by Type (2027-2032)
  5. 10.3 China Antiasthmatic Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Antiasthmatic Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Antiasthmatic Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Antiasthmatic Drug Revenue by Application (2027-2032)
  9. 10.5 China Antiasthmatic Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antiasthmatic Drug Revenue (2021-2032)
  2. 11.2 Asia Antiasthmatic Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antiasthmatic Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antiasthmatic Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Antiasthmatic Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antiasthmatic Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antiasthmatic Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antiasthmatic Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Antiasthmatic Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antiasthmatic Drug Revenue by Country
  11. 11.6.1 Asia Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antiasthmatic Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antiasthmatic Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antiasthmatic Drug Revenue (2021-2032)
  2. 12.2 SAMEA Antiasthmatic Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antiasthmatic Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antiasthmatic Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antiasthmatic Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antiasthmatic Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antiasthmatic Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antiasthmatic Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antiasthmatic Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antiasthmatic Drug Revenue by Country
  11. 12.6.1 SAMEA Antiasthmatic Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antiasthmatic Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antiasthmatic Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst